-
Pfizer Partners with CR Pharma to Expand Cancer Drug Access in China
•
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a strategic agreement with China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) to leverage their respective strengths in promoting the commercial operations of Pfizer’s established oncology drugs in China. The focus will be on drugs Aromasin (exemestane), Ibrance (palbociclib), Pharmorubicin…
-
CR Pharma’s CR Sanjiu to Sell 51% Stake in Shenghuo for RMB 1.791 Billion
•
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has announced a significant internal restructuring within its corporate structure. The company’s sub-subsidiary, China Resources Kunming Shenghuo Pharmaceutical CO., Ltd., also known as CR Sanjiu (SHE: 000999), is poised to sell its 51% stake in Shenghuo to another subsidiary of CR Pharma,…
-
Medtronic Partners with China Resources Guangdong Pharmaceutical at CIIE for Medical Equipment Development
•
US-Irish firm Medtronic (NYSE: MDT) has entered into a partnership with China-based China Resources Guangdong Pharmaceutical Co., Ltd. (HKG: 3320) at the 7th China International Import Expo (CIIE). The collaboration is aimed at developing minimally invasive surgical medical equipment to enhance patients’ diagnosis and treatment experience. Focus on GBA Policy…
-
China Resources Partners with Fosun Pharma to Expand Global Healthcare Footprint
•
China Resources (Holdings) Co. Ltd (HKG: 3320) has entered into a strategic partnership with compatriot firm Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) in the healthcare industry. The collaboration aims to accelerate the global layout and industrial development of both companies through strategic and business collaborations in…
-
China Resources Pharma Reports Strong Interim Results Amid COVID-19
•
China Resources Pharmaceutical Group Co., Ltd (HKG: 3320) has published its 2022 interim financial report, revealing a strong performance despite disruptions caused by COVID-19. During the period, the company generated revenues of HKD 12.57 billion ($1.6 billion), up 9.8% year-on-year (YOY), and net profits of HKD 6.168 billion ($785.7 million),…
